DNA methylation profile of multiple genes involved in bladder cancer among Saudi population – A pilot study

Ahmed Yaqinuddin, Amna Shoaib Siddiqui, Faizah A. Alshehri, Ayesha Rahman Ambia

Abstract


Background: To identify bladder cancer specific methylated DNA sequences for the Saudi population in order to detect and predict bladder cancer progression.

Methods: In this study, we analysed DNA methylation levels of 48 tumour suppressor genes loci in 24 bladder tissues (19 bladder cancer samples and 5 control samples taken from histologically normal bladders).  DNA Methylation analysis was done using Human Tumour Suppressor Genes EpiTect Methyl II Complete PCR Array from Qiagen TM.

Results: We identified significant difference in DNA hypermethylation levels at APC, BRCA1, CDH1, CDH13, CDKN2A, DAPK1, ESR1, FHIT, MGMT, RASSF1, SOCS1, TIMP3, TP73, VHL, WIF1 between controls and cancerous samples. It was also observed that CADM1 and DKK3 were differentially methylated in non-muscle invasive versus muscle invasive bladder cancer samples. Additionally, DNA hypermethylation of ESR1 was notified as the novel tumour suppressor gene specific for the Saudi population in bladder cancer.

Conclusion: Our findings suggest that these aberrant DNA methylation patterns in bladder cancer are disease and population specific and have a potential to develop as distinct DNA methylation-based biomarkers in future.

Keywords: Bladder Cancer; DNA methylation; Epigenetics; Hypermethylation; Tumor Markers   


Full Text:

PDF

References


Alkhateeb S, Al-Mansour M, Alotaibi M, Saadeddin A, Abusamra A, et al. Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladder. Urology Annals, (2016); 8(2): 131-135.

Al-Othman K, Al-Hathal N. Pattern of management of urologic cancer in Saudi Arabia. Urology Annals, (2010); 2(1): 21-25.

Scrimgeour EM. Bladder carcinoma and schistosomiasis haematobia in Saudi Arabia. Annals of Saudi Medicine, (1995); 15(2): 192.

Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet, (2009); 374(9685): 239-249.

Shariat SF, Karam JA, Lotan Y, Karakiewizc PI. Critical evaluation of urinary markers for bladder cancer detection and monitoring. Reviews in Urology, (2008); 10(2): 120-135.

Goodison S, Rosser CJ, Urquidi V. Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests. Molecular Diagnosis & Therapy, (2013); 17(2): 71-84.

van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. European Urology, (2005); 47(6): 736-748.

Jordahl KM, Phipps AI, Randolph TW, Tinker LF, Nassir R, et al. Mediation by differential DNA methylation of known associations between single nucleotide polymorphisms and bladder cancer risk. BMC Medical Genetics, (2020); 21(1): 228.

Mancini M, Righetto M, Zumerle S, Montopoli M, Zattoni F. The Bladder EpiCheck Test as a Non-Invasive Tool Based on the Identification of DNA Methylation in Bladder Cancer Cells in the Urine: A Review of Published Evidence. International Journal of Molecular Sciences, (2020); 21(18): 6542.

Kohler CU, Walter M, Lang K, Plottner S, Roghmann F, et al. In-Vitro Identification and In-Vivo Confirmation of DNA Methylation Biomarkers for Urothelial Cancer. Biomedicines, (2020); 8(8): 233.

Vaissiere T, Sawan C, Herceg Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutation Research, (2008); 659(1-2): 40-48.

Chihara Y, Kanai Y, Fujimoto H, Sugano K, Kawashima K, et al. Diagnostic markers of urothelial cancer based on DNA methylation analysis. BMC Cancer, (2013); 13275.

Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Annals of Oncology, (2020); 31(6): 745-759.

Tian Z, Meng L, Long X, Diao T, Hu M, et al. DNA methylation-based classification and identification of bladder cancer prognosis-associated subgroups. Cancer Cell International, (2020); 20255.

Chen X, Zhang J, Ruan W, Huang M, Wang C, et al. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer. Journal of Clinical Investigation, (2020); 130(12): 6278-6289.

Hentschel AE, Nieuwenhuijzen JA, Bosschieter J, Splunter APV, Lissenberg-Witte BI, et al. Comparative Analysis of Urine Fractions for Optimal Bladder Cancer Detection Using DNA Methylation Markers. Cancers (Basel), (2020); 12(4): 859.

Turner BM. Epigenetic responses to environmental change and their evolutionary implications. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, (2009); 364(1534): 3403-3418.

Garrigou S, Perkins G, Garlan F, Normand C, Didelot A, et al. A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker. Clincal Chemistry, (2016); 62(8): 1129-1139.

Negraes PD, Favaro FP, Camargo JL, Oliveira ML, Goldberg J, et al. DNA methylation patterns in bladder cancer and washing cell sediments: a perspective for tumor recurrence detection. BMC Cancer, (2008); 8238: 1-12.

Zhan L, Zhang B, Tan Y, Yang C, Huang C, et al. Quantitative assessment of the relationship between RASSF1A gene promoter methylation and bladder cancer (PRISMA). Medicine (Baltimore), (2017); 96(7): e6097.

Cianciulli AM, Leonardo C, Guadagni F, Marzano R, Iori F, et al. Genetic instability in superficial bladder cancer and adjacent mucosa: an interphase cytogenetic study. Human Pathology, (2003); 34(3): 214-221.

Trkova M, Babjuk M, Duskova J, Benesova-Minarikova L, Soukup V, et al. Analysis of genetic events in 17p13 and 9p21 regions supports predominant monoclonal origin of multifocal and recurrent bladder cancer. Cancer Letters, (2006); 242(1): 68-76.

Fujimoto M, Arai E, Tsumura K, Yotani T, Yamada Y, et al. Establishment of diagnostic criteria for upper urinary tract urothelial carcinoma based on genome-wide DNA methylation analysis. Epigenetics, (2020); 15(12): 1289-1301.

Rufini A, Agostini M, Grespi F, Tomasini R, Sayan BS, et al. p73 in Cancer. Genes Cancer, (2011); 2(4): 491-502.

Dominguez G, Garcia JM, Pena C, Silva J, Garcia V, et al. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. Journal of Clincal Oncology, (2006); 24(5): 805-815.

Yokomizo A, Mai M, Tindall DJ, Cheng L, Bostwick DG, et al. Overexpression of the wild type p73 gene in human bladder cancer. Oncogene, (1999); 18(8): 1629-1633.

Lindsey JC, Lusher ME, Anderton JA, Bailey S, Gilbertson RJ, et al. Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. Carcinogenesis, (2004); 25(5): 661-668.

Zhong X, Isharwal S, Naples JM, Shiff C, Veltri RW, et al. Hypermethylation of genes detected in urine from Ghanaian adults with bladder pathology associated with Schistosoma haematobium infection. PLoS One, (2013); 8(3): e59089.

Gaudet MM, Campan M, Figueroa JD, Yang XR, Lissowska J, et al. DNA hypermethylation of ESR1 and PGR in breast cancer: pathologic and epidemiologic associations. Cancer Epidemiology, Biomarkers & Prevention, (2009); 18(11): 3036-3043.

Wolff EM, Chihara Y, Pan F, Weisenberger DJ, Siegmund KD, et al. Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Research, (2010); 70(20): 8169-8178.

Fukuhara H, Kuramochi M, Fukami T, Kasahara K, Furuhata M, et al. Promoter methylation of TSLC1 and tumor suppression by its gene product in human prostate cancer. Japenes Journal of Cancer Research, (2002); 93(6): 605-609.

Lung HL, Cheung AK, Xie D, Cheng Y, Kwong FM, et al. TSLC1 is a tumor suppressor gene associated with metastasis in nasopharyngeal carcinoma. Cancer Research, (2006); 66(19): 9385-9392.

Murakami Y. Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis. Cancer Science, (2005); 96(9): 543-552.

Hayashi T, Asano H, Toyooka S, Tsukuda K, Soh J, et al. DNA methylation status of REIC/Dkk-3 gene in human malignancies. Journal of Cancer Research and Clinical Oncology, (2012); 138(5): 799-809.

Lee EJ, Jo M, Rho SB, Park K, Yoo YN, et al. Dkk3, downregulated in cervical cancer, functions as a negative regulator of beta-catenin. Internation Journal of Cancer, (2009); 124(2): 287-297.

Xu K, Chen B, Li B, Li C, Zhang Y, et al. DNMT3B silencing suppresses migration and invasion by epigenetically promoting miR-34a in bladder cancer. Aging (Albany NY), (2020); 12(23): 23668-23683.

Wu Y, Jiang G, Zhang N, Liu S, Lin X, et al. HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria. European Urology Focus, (2020); 6(2): 284-291.

Liu B, Sun W, Gao W, Li L, Cao Z, et al. microRNA-451a promoter methylation regulated by DNMT3B expedites bladder cancer development via the EPHA2/PI3K/AKT axis. BMC Cancer, (2020); 20(1): 1019.

Yan YL, Huang ZN, Zhu Z, Cui YY, Li MQ, et al. Downregulation of TET1 Promotes Bladder Cancer Cell Proliferation and Invasion by Reducing DNA Hydroxymethylation of AJAP1. Fronteirs in Oncology, (2020); 10667.

Rose M, Bringezu S, Godfrey L, Fiedler D, Gaisa NT, et al. ITIH5 and ECRG4 DNA Methylation Biomarker Test (EI-BLA) for Urine-Based Non-Invasive Detection of Bladder Cancer. Internation Journal of Molecular Sciences, (2020); 21(3).




DOI: http://dx.doi.org/10.62940/als.v8i3.1170

Refbacks

  • There are currently no refbacks.